Vaderis lands $152m and opens Phase III in rare bleeding disorder
Swiss rare disease biotech Vaderis Therapeutics has closed an oversubscribed $152 million series B private placement and started HEROIC, a global Phase III study of engasertib in hereditary hemorrhagic telangiectasia (HHT), a genetic vascular disorder with no approved therapies anywhere in the world.
The round was co-led by the life sciences team at Goldman Sachs Alternatives, part of Goldman Sachs (NYSE: GS), and TCGX, with participation from Omega Funds, EQT Life Sciences, part of Swedish investment group EQT (Nasdaq Stockholm: EQT), Perceptive Advisors and Kalehua Capital. Existing backers Medicxi and Droia also took part.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze